sales@businessmarketinsights.com   UK: +442030260021  , US: +16467917070  , Toll Free: 1800 121 6455
Pharmaceuticals Middle East and Africa Cardiometabolic Diseases Market...

2028年までの中東およびアフリカの心臓代謝疾患市場予測 - 新型コロナウイルス感染症の影響と地域分析（心血管疾患（CVD）、2型糖尿病、高血圧、肥満）、治療法（ACE阻害剤、利尿薬、グルコファージなど）、用量（錠剤、注射）、投与経路（経口、静脈内）、エンドユーザー（病院、診療所、在宅医療環境）、流通チャネル（病院の薬局、小売薬局、オンライン薬局）

TIPRE00026138 | Pages: 154 | Pharmaceuticals | Dec 2021 | Type: Regional | Status: Published

市場紹介

心臓代謝疾患は、以下のような一連の異常と症状を特徴としています。個人が心血管疾患を発症するリスク。高血圧、肥満、インスリン抵抗性、脂質異常症、コレステロールプロファイル（LDL）低下、耐糖能などが症状の一部です。心メタボリックシンドロームに罹患している人は、2 型糖尿病、脳卒中、冠動脈疾患 (CAD)、心血管疾患 (CVD) など、他のいくつかの生命を脅かす病気にかかりやすいです。

さらに、心臓代謝性疾患の有病率の増加により、予測期間中の市場の成長が促進されると予想されます。しかし、低中所得国 (LMIC) における CVD の過小診断により、中東およびアフリカの心臓代謝疾患市場の成長が制限されています。

パンデミックにより、心血管疾患の需要が増加しました。在宅医療現場で使用できる医療機器。この地域では、集中治療室（ICU）に入院する患者の数が増加していることが観察されている。薬剤数の増加により、ストレスのかかる医療システムに診断および治療上の複数の課題が生じ、医療機器や医薬品の増加につながっています。また、慢性疾患の症例も増加しており、その結果、ウイルスと戦うための薬物の使用が増加しています。新型コロナウイルス感染症（COVID-19）のパンデミックが蔓延する中、アンジオテンシン変換酵素阻害剤（ACEi）やアンジオテンシン変換遮断薬（ARB）など、特定の血圧治療薬の可能性について懸念が生じている。現在の重症急性呼吸器症候群コロナウイルス 2 (SARS-CoV-2) は、膜結合アンジオテンシン変換酵素 2 (ACE2) 受容体を使用して宿主細胞への侵入を促進します。このパンデミックにより、この地域の心臓代謝性疾患市場で活動するさまざまな製薬メーカーの事業運営が強化されました。

市場の概要とダイナミクス

中東およびアフリカの心臓代謝疾患市場は、2021 年の 43 億 900 万米ドルから 2028 年までに 50 億 850 万米ドルに達すると予測されています。 2021 年から 2028 年にかけて 2.2% の CAGR で成長すると予想されています。CMD ベースの薬剤候補パイプラインは、高血圧、糖尿病、炎症性疾患を含む幅広い治療用途に拡大しています。大小を問わず多くの製薬会社が、いくつかの低分子薬の開発に携わっています。たとえば、アストラゼネカは、初期から後期の心血管、腎臓、代謝（CVRM）領域で 25 を超える治療法と治療の組み合わせを持っています。先進技術に基づいて、CMD の治療用にいくつかの製品が導入されています。さらに、CMDに関連する研究への投資の増加により、心臓代謝疾患市場が大きく推進されています。これらすべての投資は、この中東およびアフリカの心臓代謝疾患市場の成長に前向きに反映されています。

主要市場セグメント

種類の観点からは、2020 年に心血管疾患セグメントが中東およびアフリカの心臓代謝疾患市場で最大のシェアを占めました。治療の観点からは、ACE 阻害剤セグメントが最大のシェアを占めました。錠剤セグメントは、2020年の中東およびアフリカの心臓代謝性疾患市場で最大のシェアを占めました。用量の点では、錠剤セグメントが2020年の中東およびアフリカの心臓代謝性疾患市場で最大のシェアを占めました。投与経路の観点からは、経口錠剤が使用されています。このセグメントは、2020年に中東およびアフリカの心臓代謝性疾患市場で最大のシェアを占めました。エンドユーザーの観点から見ると、病院セグメントは2020年に中東およびアフリカの心臓代謝性疾患市場で最大のシェアを占めました。さらに、流通チャネルに基づくと、 、病院薬局セグメント は、2020 年に最大の市場シェアを保持しました。

リストされている主要な供給元と企業

中東およびアフリカの心臓代謝疾患市場に関するこのレポートを作成するために参照したいくつかの主要な一次および二次情報源は、企業の Web サイト、年次報告書、財務報告書、政府文書、統計データベースなど。このレポートに記載されている主要企業は、バイエル AG、ノバルティス AG、ベーリンガー インゲルハイム インターナショナル Gmbh、ノボ ノルディスク A/S、アストラゼネカです。

購入理由レポート

  • 中東およびアフリカの心臓代謝疾患市場を理解するため状況を把握し、高い収益を保証できる市場セグメントを特定する
  • 絶えず変化する市場環境を理解し、競争で優位に立つため
  • 最も売上が見込めるセグメントを特定することで、中東およびアフリカの心臓代謝疾患市場における合併・買収およびパートナーシップ取引を効率的に計画するため
  • 知識豊富なビジネスを行うためさまざまなセグメントの市場パフォーマンスの知覚的かつ包括的な分析に基づく決定
  • さまざまなセグメントに基づいて、中東およびアフリカの心臓代謝疾患市場の市場収益予測を取得します。期間 2021 ～ 2028 年

中東およびアフリカの心血管代謝疾患市場セグメンテーション

< p>タイプ別

  • 心血管疾患（CVD）
  • 2 型糖尿病
  • 高血圧
  • 肥満

< scan>治療法別

  • ACE阻害剤
  • 利尿剤
  • グルコファージ
  • その他

投与量別

  • タブレット
  • 注射
< p>投与経路別

  • 経口
  • 静脈内 

エンド ユーザーによる

  • 病院
  • クリニック
  • ホームケア設定

作成者流通チャネル

  • 病院薬局
  • 小売薬局
  • オンライン薬局

国別

  • 中東とアフリカ
  • アラブ首長国連邦
  • サウジアラビア
  • 南アフリカ
  • 中東およびアフリカのその他の地域

記載されている企業

  • バイエル AG                         
  • ノバルティス AG               ;     
  • ベーリンガー インゲルハイム インターナショナル Gmbh
  • ノボ ノルディスク A/S       
  • アストラゼネカ                  

TABLE OF CONTENTS

1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.7        Middle East and Africa Cardiometabolic Diseases market – By Country

2.           Middle East and Africa Cardiometabolic Diseases Market – Key Takeaways

3.        Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           Middle East and Africa Cardiometabolic Diseases Market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.3         Expert Opinions

5.           Middle East and Africa Cardiometabolic Diseases Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Increasing Prevalence of Cardiometabolic Diseases

5.1.2        Innovation in Cardiometabolic Diseases Therapeutics

5.2         Market Restraints

5.2.1        Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)

5.3         Market Opportunities

5.3.1        Technological Advancements in CMD Diagnosis

5.4         Future Trends

5.4.1        Personalized Treatment for CMDs

5.5         Impact Analysis

6.           Middle East and Africa Cardiometabolic Diseases Market – Regional Analysis

6.1         Middle East and Africa Cardiometabolic Diseases Market Revenue Forecast And Analysis

7.           Middle East and Africa Cardiometabolic Diseases Market Analysis – By Type

7.1         Overview

7.2         Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)

7.3         Cardiovascular Disease (CVD)

7.3.1        Overview

7.3.2        Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

7.4         Hypertension

7.4.1        Overview

7.4.2        Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

7.5         Type 2 Diabetes

7.5.1        Overview

7.5.2        Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

7.6         Obesity

7.6.1        Overview

7.6.2        Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

8.           Middle East and Africa Cardiometabolic Diseases Market Analysis – By Treatment

8.1         Overview

8.2         Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)

8.3         ACE inhibitors

8.3.1        Overview

8.3.2        ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)

8.4         Diuretics

8.4.1        Overview

8.4.2        Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

8.5         Glucophage

8.5.1        Overview

8.5.2        Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

8.6         Others

8.6.1        Overview

8.6.2        Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

9.           Middle East and Africa Cardiometabolic Diseases Market Analysis – By Dosage

9.1         Overview

9.2         Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)

9.3         Tablet

9.3.1        Overview

9.3.2        Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

9.4         Injection

9.4.1        Overview

9.4.2        Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

10.        Middle East and Africa Cardiometabolic Diseases Market Analysis – By Route of Administration

10.1      Overview

10.2      Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)

10.3      Oral

10.3.1     Overview

10.3.2     Oral Market Revenue and Forecast to 2028 (US$ Mn)

10.4      Intravenous

10.4.1     Overview

10.4.2     Intravenous Market Revenue and Forecast to 2028 (US$ Mn)

11.        Middle East and Africa Cardiometabolic Diseases Market Analysis – By End User

11.1      Overview

11.2      Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)

11.3      Clinic

11.3.1     Overview

11.3.2     Clinic Market Revenue and Forecast to 2028 (US$ Mn)

11.4      Hospital

11.4.1     Overview

11.4.2     Hospital Market Revenue and Forecast to 2028 (US$ Mn)

11.5      Homecare Settings

11.5.1     Overview

11.5.2     Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)

12.        Middle East and Africa Cardiometabolic Diseases Market Analysis – By Distribution Channel

12.1      Overview

12.2      Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)

12.3      Hospital Pharmacy

12.3.1     Overview

12.3.2     Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

12.4      Retail Pharmacy

12.4.1     Overview

12.4.2     Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

12.5      Online Pharmacy

12.5.1     Overview

12.5.2     Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

13.        Middle East and Africa Cardiometabolic Diseases Market – Geographic Analysis

13.1      Middle East and Africa: Cardiometabolic Diseases Market

13.1.1     Overview

13.1.2     Middle East & Africa: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)

13.1.3     Middle East & Africa: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)

13.1.4     Middle East & Africa: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)

13.1.5     Middle East & Africa: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)

13.1.6     Middle East & Africa: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

13.1.7     Middle East & Africa: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)

13.1.8     Middle East & Africa: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

13.1.9     Middle East and Africa: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)

13.1.9.1       Saudi Arabia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)

13.1.9.1.1       Saudi Arabia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)

13.1.10  Saudi Arabia: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)

13.1.11  Saudi Arabia: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)

13.1.12  Saudi Arabia: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)

13.1.13  Saudi Arabia: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

13.1.14  Saudi Arabia: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)

13.1.15  Saudi Arabia: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

13.1.15.1    UAE: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)

13.1.15.1.1    UAE: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)

13.1.15.1.2    UAE: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)

13.1.16  UAE: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)

13.1.17  UAE: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)

13.1.18  UAE: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)

13.1.19  UAE: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

13.1.20  UAE: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)

13.1.21  UAE: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

13.1.21.1    South Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)

13.1.21.1.1    South Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)

13.1.22  South Africa: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)

13.1.23  South Africa: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)

13.1.24  South Africa: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)

13.1.25  South Africa: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

13.1.26  South Africa: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)

13.1.27  South Africa: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

13.1.27.1    Rest of Middle East and Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)

13.1.27.1.1    Rest of Middle East and Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)

13.1.28  Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)

13.1.29  Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)

13.1.30  Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)

13.1.31  Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

13.1.32  Rest of Middle East and Africa: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)

13.1.33  Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

14.        Impact of COVID-19 Pandemic on Middle East and Africa Cardiometabolic Diseases Market

14.1      Middle East and Africa: Impact Assessment of COVID-19 Pandemic

15.        Middle East and Africa Cardiometabolic Diseases Market – Industry Landscape

15.1      Overview

15.2      Growth Strategies in the Cardiometabolic Diseases Market (%)

15.3      Organic Developments

15.3.1     Overview

15.4      Inorganic Developments

15.4.1     Overview

16.        Company Profiles

16.1      Bayer AG

16.1.1     Key Facts

16.1.2     Business Description

16.1.3     Products and Services

16.1.4     Financial Overview

16.1.5     SWOT Analysis

16.1.6     Key Developments

16.2      Novartis AG

16.2.1     Key Facts

16.2.2     Business Description

16.2.3     Products and Services

16.2.4     Financial Overview

16.2.5     SWOT Analysis

16.2.6     Key Developments

16.3      Boehringer Ingelheim International GmbH

16.3.1     Key Facts

16.3.2     Business Description

16.3.3     Products and Services

16.3.4     Financial Overview

16.3.5     SWOT Analysis

16.3.6     Key Developments

16.4      Novo Nordisk A/S

16.4.1     Key Facts

16.4.2     Business Description

16.4.3     Products and Services

16.4.4     Financial Overview

16.4.5     SWOT Analysis

16.4.6     Key Developments

16.5      AstraZeneca

16.5.1     Key Facts

16.5.2     Business Description

16.5.3     Products and Services

16.5.4     Financial Overview

16.5.5     SWOT Analysis

16.5.6     Key Developments

17.        Appendix

17.1      About The Insight Partners

17.2      Glossary of Terms

 


LIST OF TABLES

Table 1.             Middle East & Africa Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)

Table 2.             Middle East & Africa Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)

Table 3.             Middle East & Africa Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)

Table 4.             Middle East & Africa Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 5.             Middle East & Africa Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)

Table 6.             Middle East & Africa Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 7.             Saudi Arabia Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)

Table 8.             Saudi Arabia Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)

Table 9.             Saudi Arabia Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)

Table 10.          Saudi Arabia Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 11.          Saudi Arabia Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)

Table 12.          Saudi Arabia Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 13.          UAE Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)

Table 14.          UAE Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)

Table 15.          UAE Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)

Table 16.          UAE Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 17.          UAE Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)

Table 18.          UAE Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 19.          South Africa Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)

Table 20.          South Africa Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)

Table 21.          South Africa Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)

Table 22.          South Africa Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 23.          South Africa Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)

Table 24.          South Africa Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 25.          Rest of Middle East and Africa Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)

Table 26.          Rest of Middle East and Africa Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)

Table 27.          Rest of Middle East and Africa Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)

Table 28.          Rest of Middle East and Africa Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 29.          Rest of Middle East and Africa Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)

Table 30.          Rest of Middle East and Africa Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 31.          Organic Developments in the Cardiometabolic Diseases Market

Table 32.          Inorganic Developments in the Cardiometabolic Diseases Market

Table 33.          Glossary of Terms, Middle East and Africa Cardiometabolic Diseases Market

LIST OF FIGURES

Figure 1.           Middle East and Africa Cardiometabolic Diseases Market Segmentation

Figure 2.           Middle East and Africa Cardiometabolic Diseases Market Overview

Figure 3.           Cardiovascular Disease (CVD) Segment Held Largest Share of Type of Middle East and Africa Cardiometabolic Diseases Market

Figure 4.           Middle East and Africa Cardiometabolic Diseases Market – Leading Country Markets (US$ Million)

Figure 5.           Middle East and Africa Cardiometabolic Diseases Market, Industry Landscape

Figure 6.           Middle East and Africa PEST Analysis

Figure 7.           Middle East and Africa Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints

Figure 8.           Middle East and Africa Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028

Figure 9.           Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)

Figure 10.        Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 11.        Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 12.        Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 13.        Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 14.        Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)

Figure 15.        ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 16.        Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 17.        Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 18.        Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 19.        Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)

Figure 20.        Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 21.        Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 22.        Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)

Figure 23.        Oral Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 24.        Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 25.        Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)

Figure 26.        Clinic Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 27.        Hospital Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 28.        Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 29.        Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)

Figure 30.        Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 31.        Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 32.        Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 33.        Middle East and Africa: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million)

Figure 34.        Middle East & Africa Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Million)

Figure 35.        Middle East and Africa: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)

Figure 36.        Saudi Arabia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)

Figure 37.        UAE: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)

Figure 38.        South Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)

Figure 39.        Rest of Middle East and Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)

Figure 40.        Impact of COVID-19 Pandemic on Middle East and Africa Cardiometabolic Diseases Market

Figure 41.        Growth Strategies in the Cardiometabolic Diseases Market (%)

 

  1. Bayer AG             
  2. Novartis AG          
  3. Boehringer Ingelheim International Gmbh
  4. Novo Nordisk A/S            
  5. AstraZeneca         
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East and Africa cardiometabolic diseases market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Middle East and Africa cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports
Report Name Published Date
Middle East and Africa Wind Turbine Condition Monitoring Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Component (Hardware, and S.. May 2022
Middle East and Africa Automotive System Simulation Software Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Transmission, En.. May 2022
Middle East and Africa In-Office Teeth Whitening Products Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Double-Syringe M.. May 2022
Purchase Options
Single User License
$3000
$1800
Site License
$4000
$2400
Enterprise License
$5000
$3000
GET FREE SAMPLE PDF
Inquire before Buying Inquire for Discount
Subscription Member Price: FREE
Get Subscription